The US life sciences sector saw a flurry of merger and acquisition activity at the end of 2013, and it may continue into early 2014, according to an analysis from PricewaterhouseCoopers.
Overall, 2013 saw a contraction of 13 percent in medtech sector M&A, with a total of 41 deals, but a surge of 15 deals worth a collective $4.77 billion in the fourth quarter "may signal a healthy turn for the industry," MassDevice reports.
"Healthy balance sheets, access to financing, and strong equity markets will allow [pharmaceutical/life sciences] participants to continue to seek opportunities to grow through acquisition across industry sectors," said PwC, which examined only deals that included a US company on at least one end of the deal.